RVNC - Revance Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Nashville,
United States
Type: Equity
RVNC price evolution
RVNC
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $137.88 | $179.59 | $141.51 | $136.95 |
| Short term investments | $116.59 | $120.93 | $178.49 | $137.27 |
| Net receivables | $27.68 | $25.41 | $17.04 | $15.37 |
| Inventory | $45.58 | $46.21 | $34.45 | $27.77 |
| Total current assets | $338.87 | $388.52 | $378.95 | $323.02 |
| Long term investments | $6.87 | $7.14 | $7.14 | $7.14 |
| Property, plant & equipment | $90.21 | $95.2 | $73.59 | $79.66 |
| Goodwill & intangible assets | $9.81 | $10.51 | $105.64 | $108.4 |
| Total noncurrent assets | $139.59 | $143.97 | $218.59 | $224.78 |
| Total investments | $123.46 | $128.07 | $185.63 | $144.42 |
| Total assets | $478.45 | $532.49 | $597.53 | $547.8 |
| Current liabilities | ||||
| Accounts payable | $13.81 | $4.78 | $8.35 | $13 |
| Deferred revenue | $81.16 | $89.69 | $87.65 | $87.06 |
| Short long term debt | $10.85 | $18.52 | $20.77 | $23.09 |
| Total current liabilities | $89.22 | $82.16 | $74.08 | $77.98 |
| Long term debt | $467.58 | $469.38 | $411.62 | $412.63 |
| Total noncurrent liabilities | $540.83 | $556.53 | $496.67 | $496.49 |
| Total debt | $478.43 | $487.9 | $432.39 | $435.72 |
| Total liabilities | $630.06 | $638.69 | $570.75 | $574.47 |
| Shareholders' equity | ||||
| Retained earnings | -$2078.36 | -$2022.66 | -$1881.48 | -$1814.17 |
| Other shareholder equity | $0.01 | -$0.01 | -$0.06 | -$0.13 |
| Total shareholder equity | -$151.6 | -$106.2 | $26.79 | -$26.67 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $137.88 | $115.02 | $115.67 | $337 |
| Short term investments | $116.59 | $231.74 | $114.45 | $102.95 |
| Net receivables | $27.68 | $11.34 | $3.35 | $1.83 |
| Inventory | $45.58 | $18.32 | $10.15 | $5.88 |
| Total current assets | $338.87 | $374.73 | $246.12 | $450 |
| Long term investments | $6.87 | |||
| Property, plant & equipment | $90.21 | $67.75 | $69 | $47.13 |
| Goodwill & intangible assets | $9.81 | $104.18 | $202.3 | $218.31 |
| Total noncurrent assets | $139.59 | $207.17 | $285.05 | $270.22 |
| Total investments | $123.46 | $231.74 | $114.45 | $102.95 |
| Total assets | $478.45 | $581.9 | $531.16 | $720.22 |
| Current liabilities | ||||
| Accounts payable | $13.81 | $4.55 | $10.6 | $12.66 |
| Deferred revenue | $81.16 | $85.44 | $83.51 | $85.14 |
| Short long term debt | $10.85 | $4.91 | $4.75 | $4.44 |
| Total current liabilities | $89.22 | $75.68 | $67.29 | $60.96 |
| Long term debt | $467.58 | $379.37 | $319.77 | $207.67 |
| Total noncurrent liabilities | $540.83 | $493.62 | $395.4 | $284.97 |
| Total debt | $478.43 | $418.47 | $324.51 | $212.11 |
| Total liabilities | $630.06 | $569.3 | $462.69 | $345.93 |
| Shareholders' equity | ||||
| Retained earnings | -$2078.36 | -$1754.37 | -$1397.95 | -$1126.29 |
| Other shareholder equity | $0.01 | -$0.37 | -$0.02 | |
| Total shareholder equity | -$151.6 | $12.6 | $68.47 | $374.29 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $69.8 | $56.78 | $58.13 | $49.33 |
| Cost of revenue | $17.47 | $19.41 | $21.31 | $16.17 |
| Gross Profit | $52.33 | $37.36 | $36.83 | $33.16 |
| Operating activities | ||||
| Research & development | $20.37 | $13.06 | $22.81 | $23.18 |
| Selling, general & administrative | $85.24 | $69.09 | $77.38 | $66.01 |
| Total operating expenses | $106.28 | $176.66 | $102.33 | $91.19 |
| Operating income | -$53.95 | -$139.29 | -$65.5 | -$58.03 |
| Income from continuing operations | ||||
| EBIT | -$50.3 | -$135.78 | -$62.95 | -$55.3 |
| Income tax expense | $0.3 | |||
| Interest expense | $5.4 | $5.09 | $4.37 | $4.5 |
| Net income | ||||
| Net income | -$55.7 | -$141.18 | -$67.32 | -$59.79 |
| Income (for common shares) | -$55.7 | -$141.18 | -$67.32 | -$59.79 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $234.04 | $132.56 | $77.8 | $15.32 |
| Cost of revenue | $74.36 | $51.67 | $23.41 | $4.77 |
| Gross Profit | $159.68 | $80.9 | $54.39 | $10.56 |
| Operating activities | ||||
| Research & development | $79.41 | $101.29 | $116.25 | $125.8 |
| Selling, general & administrative | $297.73 | $223.93 | $198.82 | $151.85 |
| Total operating expenses | $476.45 | $422.86 | $329.06 | $283.72 |
| Operating income | -$316.78 | -$341.96 | -$274.68 | -$273.16 |
| Income from continuing operations | ||||
| EBIT | -$304.33 | -$339.25 | -$275.04 | -$269.56 |
| Income tax expense | $0.3 | $0.7 | -$2.62 | |
| Interest expense | $19.36 | $16.47 | $6.27 | $15.15 |
| Net income | ||||
| Net income | -$323.99 | -$356.42 | -$281.31 | -$282.09 |
| Income (for common shares) | -$323.99 | -$356.42 | -$281.31 | -$282.09 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$55.7 | -$141.18 | -$67.32 | -$59.79 |
| Operating activities | ||||
| Depreciation | $1.42 | $2.13 | $3.53 | $6.62 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $8.85 | $10.29 | $15.6 | $13.08 |
| Total cash flows from operations | -$42.73 | -$50.96 | -$53.38 | -$69.5 |
| Investing activities | ||||
| Capital expenditures | -$1.78 | -$4.5 | $0.27 | -$0.87 |
| Investments | $4.15 | $56.09 | -$39.8 | $96.19 |
| Total cash flows from investing | $2.37 | $51.59 | -$39.53 | $95.32 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.26 | $0.06 | $104.67 | $9.48 |
| Net borrowings | -$2.74 | $41.18 | -$6.64 | -$2.49 |
| Total cash flows from financing | -$1.63 | $37.46 | $97.47 | $3.27 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$41.99 | $38.08 | $4.56 | $29.08 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$323.99 | -$356.42 | -$281.31 | -$282.09 |
| Operating activities | ||||
| Depreciation | $13.69 | $39.15 | $19.85 | $10.25 |
| Business acquisitions & disposals | -$0.82 | |||
| Stock-based compensation | $47.81 | $52.34 | $43.43 | $36.45 |
| Total cash flows from operations | -$216.57 | -$193.55 | -$221.54 | -$178.5 |
| Investing activities | ||||
| Capital expenditures | -$6.89 | -$3.21 | -$10.38 | -$4.22 |
| Investments | $116.63 | -$135.59 | -$19.29 | $17.16 |
| Total cash flows from investing | $109.74 | -$138.8 | -$29.66 | $12.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $115.47 | $252.83 | $38.39 | $90.84 |
| Net borrowings | $29.31 | $85.01 | $278.31 | |
| Total cash flows from financing | $136.57 | $331.69 | $29.87 | $331.48 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $29.73 | -$0.65 | -$221.33 | $165.11 |
News
Fundamentals
| Market cap | $333.38M |
|---|---|
| Enterprise value | $673.93M |
| Shares outstanding | 87.96M |
| Revenue | $234.04M |
|---|---|
| EBITDA | -$290.64M |
| EBIT | -$304.33M |
| Net Income | -$323.99M |
| Revenue Q/Q | 39.82% |
| Revenue Y/Y | 76.55% |
| P/E ratio | -1.03 |
|---|---|
| EV/Sales | 2.88 |
| EV/EBITDA | -2.32 |
| EV/EBIT | -2.21 |
| P/S ratio | 1.42 |
| P/B ratio | -2.20 |
| Book/Share | -1.72 |
| Cash/Share | 1.57 |
| EPS | -$3.68 |
|---|---|
| ROA | -60.10% |
| ROE | 502.90% |
| Debt/Equity | -4.16 |
|---|---|
| Net debt/EBITDA | -1.69 |
| Current ratio | 3.80 |
| Quick ratio | 3.29 |